Detalles de la búsqueda
1.
Phase 1 trial of bemcentinib (BGB324), a first-in-class, selective AXL inhibitor, with docetaxel in patients with previously treated advanced non-small cell lung cancer.
Lung Cancer
; 182: 107291, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37423058
Resultados
1 -
1
de 1
1
Próxima >
>>